Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...
- Bias Rating
- Reliability
25% ReliableLimited
- Policy Leaning
10% Center
- Politician Portrayal
N/A
Continue For Free
Create your free account to see the in-depth bias analytics and more.
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates.
Bias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
20% Positive
- Liberal
- Conservative
| Sentence | Sentiment | Bias |
|---|---|---|
Unlock this feature by upgrading to the Pro plan. | ||
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
51% : Its pipeline technology platform, Mutation-Allostery-Pharmacology, is targeting mutations in cancer, with drugs such as BDTX-4933 and BDTX-1535 under development.40% : The company has recently dosed the first patient in a Phase 2 trial of BDTX-1535 for non-classical EGFRm NSCLC and is on track to present clinical data in the third quarter of 2024 for this trial.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.
